PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
BioMarin Pharmaceutical Inc. (BMRN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US09061G1013

CUSIP

09061G101

Sector

Healthcare

IPO Date

Jul 23, 1999

Highlights

Market Cap

$12.81B

EPS (TTM)

$1.66

PE Ratio

40.48

PEG Ratio

0.42

Total Revenue (TTM)

$2.75B

Gross Profit (TTM)

$2.14B

EBITDA (TTM)

$507.32M

Year Range

$61.15 - $99.25

Target Price

$97.35

Short %

3.04%

Short Ratio

3.74

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
BMRN vs. CRSP BMRN vs. CPRX BMRN vs. JAZZ BMRN vs. KNSA BMRN vs. BMTX BMRN vs. VRTX BMRN vs. RCKT BMRN vs. AVGO BMRN vs. VOO BMRN vs. LLY
Popular comparisons:
BMRN vs. CRSP BMRN vs. CPRX BMRN vs. JAZZ BMRN vs. KNSA BMRN vs. BMTX BMRN vs. VRTX BMRN vs. RCKT BMRN vs. AVGO BMRN vs. VOO BMRN vs. LLY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in BioMarin Pharmaceutical Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


300.00%400.00%500.00%600.00%JulyAugustSeptemberOctoberNovemberDecember
392.88%
332.75%
BMRN (BioMarin Pharmaceutical Inc.)
Benchmark (^GSPC)

Returns By Period

BioMarin Pharmaceutical Inc. had a return of -32.91% year-to-date (YTD) and -32.99% in the last 12 months. Over the past 10 years, BioMarin Pharmaceutical Inc. had an annualized return of -3.66%, while the S&P 500 had an annualized return of 11.01%, indicating that BioMarin Pharmaceutical Inc. did not perform as well as the benchmark.


BMRN

YTD

-32.91%

1M

4.46%

6M

-23.13%

1Y

-32.99%

5Y*

-5.27%

10Y*

-3.66%

^GSPC (Benchmark)

YTD

23.11%

1M

-0.36%

6M

7.02%

1Y

23.15%

5Y*

12.80%

10Y*

11.01%

Monthly Returns

The table below presents the monthly returns of BMRN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-8.65%-2.04%1.23%-7.53%-7.05%9.67%2.43%8.16%-22.94%-6.26%0.21%-32.91%
202311.46%-13.66%-2.36%-1.23%-9.48%-0.30%1.44%3.92%-3.17%-7.95%11.82%5.86%-6.83%
20220.32%-11.86%-1.31%5.51%-7.65%10.30%3.84%3.66%-4.97%2.19%16.56%2.49%17.14%
2021-5.60%-6.46%-2.48%3.19%-0.80%7.94%-8.04%9.75%-8.22%2.51%8.91%2.39%0.75%
2020-1.24%8.23%-6.50%8.90%15.79%15.76%-2.86%-34.87%-2.50%-2.17%5.74%11.42%3.71%
201915.29%-5.00%-4.75%-3.71%-3.85%4.15%-7.39%-5.37%-10.21%8.62%10.24%4.76%-0.70%
20181.19%-10.04%-0.12%3.01%8.18%4.27%6.75%-0.58%-3.01%-4.95%4.19%-11.33%-4.51%
20175.78%7.19%-6.55%9.18%-8.56%3.63%-3.40%2.80%3.19%-11.80%4.52%3.93%7.64%
2016-29.34%10.61%0.75%2.67%5.87%-13.22%27.79%-5.56%-1.46%-12.97%6.35%-3.26%-20.92%
20157.48%10.20%16.39%-10.09%12.07%8.93%6.94%-11.64%-18.51%11.13%-18.52%9.85%15.88%
2014-2.09%17.60%-15.79%-14.63%-0.46%7.33%-0.63%15.21%1.32%14.33%8.75%0.76%28.50%
201311.57%5.61%7.40%5.36%-4.42%-11.10%15.98%1.27%10.23%-12.88%12.01%-0.11%42.99%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BMRN is 7, meaning it’s performing worse than 93% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BMRN is 77
Overall Rank
The Sharpe Ratio Rank of BMRN is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of BMRN is 88
Sortino Ratio Rank
The Omega Ratio Rank of BMRN is 66
Omega Ratio Rank
The Calmar Ratio Rank of BMRN is 1515
Calmar Ratio Rank
The Martin Ratio Rank of BMRN is 44
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for BMRN, currently valued at -1.04, compared to the broader market-4.00-2.000.002.00-1.041.90
The chart of Sortino ratio for BMRN, currently valued at -1.30, compared to the broader market-4.00-2.000.002.004.00-1.302.54
The chart of Omega ratio for BMRN, currently valued at 0.80, compared to the broader market0.501.001.502.000.801.35
The chart of Calmar ratio for BMRN, currently valued at -0.56, compared to the broader market0.002.004.006.00-0.562.81
The chart of Martin ratio for BMRN, currently valued at -1.64, compared to the broader market0.0010.0020.00-1.6412.39
BMRN
^GSPC

The current BioMarin Pharmaceutical Inc. Sharpe ratio is -1.04. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of BioMarin Pharmaceutical Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-1.04
1.90
BMRN (BioMarin Pharmaceutical Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


BioMarin Pharmaceutical Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-56.62%
-3.58%
BMRN (BioMarin Pharmaceutical Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the BioMarin Pharmaceutical Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the BioMarin Pharmaceutical Inc. was 90.58%, occurring on Aug 27, 2002. Recovery took 1350 trading sessions.

The current BioMarin Pharmaceutical Inc. drawdown is 56.62%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-90.58%Mar 2, 2000624Aug 27, 20021350Jan 8, 20081974
-74.89%Feb 15, 2008267Mar 9, 2009837Jul 2, 20121104
-58.47%Jul 21, 20152349Nov 18, 2024
-38%Sep 28, 199965Dec 29, 199932Feb 14, 200097
-33.02%Feb 28, 201497Jul 17, 201476Nov 3, 2014173

Volatility

Volatility Chart

The current BioMarin Pharmaceutical Inc. volatility is 8.39%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%JulyAugustSeptemberOctoberNovemberDecember
8.39%
3.64%
BMRN (BioMarin Pharmaceutical Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of BioMarin Pharmaceutical Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of BioMarin Pharmaceutical Inc. compared to its peers in the Biotechnology industry.


PE Ratio
200.0400.0600.040.5
The chart displays the price to earnings (P/E) ratio for BMRN in comparison to other companies of the Biotechnology industry. Currently, BMRN has a PE value of 40.5. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.
PEG Ratio
-1,000.0-800.0-600.0-400.0-200.00.00.4
The chart displays the price to earnings to growth (PEG) ratio for BMRN in comparison to other companies of the Biotechnology industry. Currently, BMRN has a PEG value of 0.4. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for BioMarin Pharmaceutical Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab